661
Participants
Start Date
June 21, 2011
Primary Completion Date
September 30, 2018
Study Completion Date
September 30, 2018
Atezolizumab
Atezolizumab will be administered as IV infusion at eight dose levels (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 20 mg/kg) in dose escalation cohort and at a dose which result in total drug exposure \</= exposures achieved at the MTD or MAD, will be selected for expansion cohort.
New York Oncology Hematology, P.C., Albany
Johns Hopkins Univ Med Center, Baltimore
Virginia Oncology Associates, Norfolk
Carolina BioOncology Institute; Can Therapy & Res Ctr, Huntersville
Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse
Moffitt Cancer Center, Tampa
Sarah Cannon Research Inst., Nashville
Vanderbilt, Nashville
Uni of Chicago, Chicago
Centre Leon Berard, Lyon
HonorHealth Research Institute - Pima Center, Scottsdale
Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas
The Angeles Clinic, Los Angeles
Stanford Univ Medical Center; Dept Central Pharmacy, Stanford
Institut Gustave Roussy; Drct, Villejuif
Yale Cancer Center, New Haven
Massachusetts General Hospital., Boston
Beth Israel Deaconess Med Ctr, Boston
Dana Farber Can Ins, Boston
Hospital Universitari Vall d'Hebron, Barcelona
Barts & London School of Med; Medical Oncology, London
Lead Sponsor
Genentech, Inc.
INDUSTRY